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Abstract
Background: Controversy surrounds the role of fetal cardiotocography (CTG) in
the antenatal management of pregnancy complicated with gestational diabetes
mellitus (GDM).
Aim: The aim was to investigate whether antenatal CTG aids the management
in pregnancy complicated by GDM.
Materials and Methods: A prospective audit of 1404 consecutive antenatal
CTGs in women diagnosed with GDM. Outcomes for all CTGs were audited to
determine if the CTGs altered pregnancy management.
Results: In women requiring combination therapy (diet and medication), 43
CTGs were required to change management of a pregnancy. In women
managed by diet alone with a secondary pregnancy complication, 161 CTGs
were required to change management. In women managed by diet alone with
no secondary pregnancy complication, CTGs did not change management.
Conclusions: Antenatal CTGs are not recommended in women with GDM
managed by diet alone with no secondary pregnancy complication. Antenatal
CTGs are recommended in women with GDM who require combination therapy
(diet and medication). The role of CTG in women managed by diet alone with a
secondary pregnancy complication should be based upon the nature of the
complication.
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Introduction
Gestational diabetes mellitus (GDM) is a common condition
characterised by glucose intolerance first diagnosed during pregnancy.1,2 The
prevalence of GDM in Australia was estimated at 4.6% in 2006.3 This is lower
than the more recent 5.2%, reported by a large scale Australian study,
suggesting that the prevalence of GDM is rising.4 . GDM pregnancies have an
increased risk of a number of maternal and fetal complications including
gestational hypertension, pre-eclampsia, caesarean delivery, development of
type 2 diabetes postpartum, fetal macrosomia, birth trauma and shoulder
dystocia.5,6 The risk of maternal and fetal complications is higher in GDM
pregnancies with poor glycemic control.5,6 As a result, hypoglycemic
medications including Insulin and Metformin can be instituted in GDM
pregnancies which are unable to achieve glycemic targets with diet and
exercise, to help optimise glycemic levels.4,7 GDM pregnancies requiring
hypoglycaemic therapy are therefore at higher risk of potential complications
compared to diet controlled GDM, due to poorer initial glycemic control.4,7
Antenatal fetal surveillance is routinely performed in pregnancies
complicated by GDM.8 Common surveillance methods include ultrasonography
and cardiotocography (CTG) monitoring.8,9 In particular, CTG monitoring plays a
role in detecting pregnancies at risk of stillbirth, allowing for prompt further
testing and intervention.10,11
The fetal heart rate is determined by a balance of sympathetic and
parasympathetic stimulation of the sinoatrial node.12 This balance is mediated
through a number of neurotransmitters including catecholamines.12 Therefore,
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CTG tracings can reflect underlying fetal pathology or a physiological response
to fetal distress.12,13 A number of conditions are associated with abnormal CTG
tracings. Causes of particular concern include: cord compression or prolapse,
chorioamnionitis, fetal hypoxia and maternal hypovolemia.12,13 Specific CTG
findings that suggest fetal hypoxia and acidosis include: reduced baseline
variability, the absence of accelerations and the development of late
decelerations.14
Whilst a reactive CTG represents a well oxygenated central nervous
system and fetal wellbeing, abnormal CTGs can occur in the absence of
underlying pathology.13 For example, early decelerations often represent
compression of the fetal head in response to normal maternal contractions.12,13
In the case of GDM pregnancies, it is important to note that an abnormal CTG
may not occur as a result of GDM itself. Rather, CTG changes in GDM
pregnancies will often result from associated secondary complications such as
hypertension or intra uterine growth restriction.
There is a lack of consensus on the frequency and commencement
gestation of CTG monitoring in GDM pregnancies.15,16 Current Australian and
International guidelines recommend the frequency of CTG monitoring should be
guided by the presence of other pregnancy complications.15,16 The Australiasian
Diabetes in Pregnancy (ADIPS) Testing and Diagnosis Guidelines do not
specify recommendations for the commencement or frequency of CTG
monitoring in GDM pregnancies.8 Furthermore, the latest Australasian GDM
management guidelines written in 1998 suggest that while CTG surveillance is
commonly undertaken from 36 weeks gestation, there is no evidence to suggest
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that this affects fetal outcomes in uncomplicated GDM.15 This is further
supported by International guidelines which assert that current data is
insufficient to determine if CTG monitoring is of any benefit in well controlled
GDM pregnancies.16
There is limited research exploring the effectiveness and necessity of
CTG monitoring in GDM pregnancies.15,16 A literature search using terms
“gestational diabetes mellitus”, “gestational diabetes”, “diabetes”, “pregnancy”,
“CTG”, “management” and “adverse” in multiple combinations revealed 43
relevant abstracts, and on review, only one study that specifically examined the
effectiveness of CTG monitoring in predicting adverse events in GDM
pregnancies. This 1995 observational study by Kjos in the United States
evaluated the effectiveness of twice-weekly CTGs and amniotic fluid index on
predicting fetal distress requiring caesarean section in GDM pregnancies.11
3671 deliveries complicated by either gestational diabetes or pre-existing
diabetes were included in the study. Of these women, 2134 underwent regular
ante-partum surveillance.11 Non-reactivity during CTG was associated with
increased fetal distress (OR 3.6, 95% CI: 2.14 – 6.06).11 The presence of
decelerations on CTG was also associated with increased fetal distress (OR
3.6, 95% CI: 2.14 – 6.06).11
While this study had a substantial sample size, there were some
limitations.11 In particular, the study included women with both GDM and preexisting type 1 or type 2 diabetes.11 Additionally, GDM pregnancies managed
by diet alone and without secondary complications received ante-partum
surveillance at a significantly later gestational age (38.9±0.2 weeks, p<0.0001)
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and received fewer tests (3.2±0.2 weeks, p<0.0001) than other groups in the
study.11 Therefore, it is not known if GDM pregnancies received the same
benefit of routine CTG monitoring as type 1 and 2 diabetic pregnancies.
In the absence of research, there is debate regarding the necessity of
CTG monitoring in GDM pregnancies without secondary pregnancy
complication.17-19 Landon and Vickers, suggest that: “In well controlled
normotensive GDM pregnancies with normal fetal growth, it is probably true that
no tests for fetal well-being are required”.17 An article by Loomis also
emphasised the lack of evidence for or against fetal surveillance for women with
uncomplicated GDM.18
Further information is required to refine antenatal management in
pregnancy complicated by GDM.17-19 In particular, data are required on the
efficacy and cost-effectiveness of CTGs in aiding management in the various
GDM subgroups.17-19
Therefore the aim of this study was to determine the number of CTGs
required to effect change in clinical management in women with a GDM
pregnancy. Our primary hypothesis was that CTG monitoring would not add
value in the setting of women with a GDM pregnancy managed by diet alone
with no secondary complication.

Methods
Type of study and approvals
A prospective audit of all pregnancies diagnosed with GDM was
undertaken. The Institutional Ethics Committee determined the project fulfilled
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the criteria of an audit project as no intervention other than routine care in
accordance with clinical protocols was being undertaken and regular auditing
was already being undertaken. Therefore, the project was exempted from
formal ethics committee approval.
Patient population
All pregnant women greater than 20 weeks gestation referred for public
maternity care who resided within the referral postcodes of the Joondalup
Health Campus within the North Metropolitan Health Service of Western
Australia between 1 January 2012 to 30 June 2014 were included in the audit.
Women with a history of pre-existing Diabetes Mellitus (type 1 or 2) were
specifically excluded.
Diagnosis of GDM
All women had an OGTT between 24-30 weeks gestation in accordance
with the existing clinical guideline.20-23 Women were included in the CTG audit if
their OGTT results were consistent with a diagnosis of GDM in accordance with
IADPSG 2010 diagnostic criteria.20-23
Antenatal care protocols
All women diagnosed with GDM across the audit period received clinical
care according to the hospital guideline. Management involved an initial
consultation with a diabetic educator, dietician and obstetric doctor (registrar or
consultant). Patients commenced self-monitoring of blood sugar levels and
adopted a diabetic diet. A review visit two weeks later determined if medication,
in addition to diet, was required to achieve target blood sugar levels of
<5.5 mmol/L (fasting) and <7.0 mmol/L (2 h postprandial). 20
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As part of the hospital guideline, women with a GDM pregnancy managed
by diet alone underwent ultrasound examinations (US) at 32 and 36 weeks
gestation and cardiotocography (CTG) at 36, 37, 38 and 39 weeks gestation.
They were offered induction of labour at 40 weeks gestation.
Women with a GDM pregnancy managed with combination therapy (diet
and medication) commenced CTGs from 34 weeks and had an additional US at
34 weeks. These women were offered induction of labour at 38 weeks.
Women with a GDM pregnancy with a secondary pregnancy complication
(for example: fetal macrosomia, antepartum haemorrhage, hypertension,
polyhydramnios) had an individualized management plan of CTG and US and
were offered delivery as directed by the attending specialist.

Recording the outcome of CTGs
The attending midwife recorded the outcome of each CTG. The attending
obstetric registrar also reviewed the CTG to ensure there was concordance in
the interpretation of outcome. Where there was discordance in outcome or the
CTG was recorded as being abnormal, the case was discussed with the
attending consultant who reviewed the woman and CTG to make a decision on
management.
All staff (attending midwives, registrars and consultants) had successfully
completed the RANZCOG Fetal Surveillance Education Program
(http://www.fsep.edu.au) and achieved a pass mark in excess of 70% during the
audit period.
CTGs were recorded as reactive non stress test (RNST) or non reactive
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non stress (NRNST) in accordance with established criteria.24
NRNST were further categorized as an abnormal CTG if the attending staff
member noted a feature of concern such as a deceleration, baseline rate
abnormality (bradycardia or tachycardia) or baseline variability abnormality
(sinusoidal pattern, reduced or increased variability).
Follow up of CTGs
Patients with a RNST CTG were discharged with advice to attend the
antenatal clinic at their next scheduled appointment.
Patients with a NRNST CTG were encouraged to have a meal, go for a
walk and return for a repeat CTG within a few hours. Vibroacoustic stimulation
was occasionally applied. If the repeat CTG was a RNST women were
discharged with advice to attend the antenatal clinic at their next scheduled
appointment. If the repeat CTG was a NRNST, a biophysical profile ultrasound
(BPP) was requested. This generated a total score out of 10 (including the
CTG). A score of 8 or 10 was deemed normal and women were discharged with
advice to attend the antenatal clinic at their next scheduled appointment. An
overall score of 6 was deemed borderline and required consultant review and
possible delivery. An overall score of 4 or less was deemed abnormal and
required consultant review and delivery.
An abnormal CTG required consultant review and individualized
management.
Outcome
The primary outcome was the number of CTGs performed to elicit a
“definitive change in management” (DCM). A DCM was defined as a decision by
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a consultant to change management from the plan that had been in place prior
to the commencement of the CTG. A DCM may have involved a decision to
deliver or to increase fetal surveillance.
The secondary outcome was the cost to the healthcare system. Of note,
cost estimates included the staff time to conduct, review and document
outcomes of the CTG in the patient record. It also included the need to repeat a
CTG due to a NRNST, or order a BPP that was subsequently normal or
borderline but did not result in a DCM.
Analysis of results
We assumed it would be clinically significant if a DCM arose every 50
CTGs. Assuming a dichotomous endpoint of a CTG resulting in a DCM (yes or
no), alpha error of 0.05 and power of 80%, this could be reliably detected with a
sample size of 188 CTGs.
We were interested in outcomes for three subgroups. These were:
a) GDM pregnancy managed by diet alone;
b) GDM pregnancy managed by combination therapy (diet and medication);
c) GDM pregnancy with a secondary pregnancy complication
In order to have a sample size of 188 CTGs in each of these three
subgroups, we audited 1400 consecutive CTGs prior to analysis.
Data were presented as number and percentage, and as number needed
to treat (NNT) for each subgroup.
Costs were generated on award determinations of staff time and Medicare
Australia rebates for CTG and BPP respectively. Infrastructure costs were not
included in the model.
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Results
The demographic and pregnancy outcomes of audited women are
summarised in Table 1. Mean age was 31 years. Most women were parous and
a quarter delivered by caesarean section. Blood loss and birth trauma rates
were similar to the wider maternity cohort. Newborn birthweight (adjusted for
fetal gender) was also consistent with the background maternity population
although the incidence of birthweight adjusted for gestational age above the
90th centile was slightly increased at 12% instead of the predicted 10%. Despite
normal Apgar and cord blood levels, the rate of admission to special care
nursery was higher than the background rate at 12%.
The 357 women underwent a total of 1404 antenatal CTGs (3.9 per
woman). Of these, 1179 were initial CTGs, of which 19% (N=225) were NRNST
and were subsequently repeated to generate the total sample of 1404 CTGs. Of
the 225 repeated CTGs, 28% remained NRNST (N=63) and the patient was
referred for BPP. Overall, a total of 14 women had a DCM as a result of the
CTG process. Of these, 8 were as a result of an abnormal CTG and 6 due to an
abnormal BPP after two NRNST.
Of the 357 women with GDM, 262 (74%) were managed with diet alone,
whereas 95 required combined therapy with diet and medication to achieve
optimal glycemic control (Metformin or Insulin).
Overall, 135 women (38%) were diagnosed with a secondary pregnancy
complication. These complications were fetal macrosomia (N=58), hypertensive
disease of pregnancy (N=33; pre-existing hypertension, pregnancy induced
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hypertension or pre eclampsia), reduced fetal movements (N=18), antepartum
haemorrhage (N=8), threatened preterm labour (N=8), polyhydramnios (N=6),
and other (N=12). Reduced fetal movements were defined as less than 10
movements in a two hour period chosen by the mother as a period when her
baby was usually active. Eight women had more than one secondary
complication.
Figure 1 summarises the outcomes of the three subgroups (GDM requiring
combination therapy, GDM managed by diet alone with a secondary pregnancy
complication, and GDM managed by diet alone without a secondary pregnancy
complication).
In the subgroup of 95 women with GDM requiring combination therapy,
475 CTGs were performed. A DCM occurred in 11 of these 95 women. The
number of CTGs required to effect a DCM (NNT) was 43.
In the subgroup of 79 women with GDM managed by diet alone identified
with a secondary pregnancy complication, 484 CTGs were performed. A DCM
occurred in 3 of these 79 women. The number of CTGs required to effect a
DCM (NNT) was 161.
In the subgroup of 183 women with GDM managed by diet alone without a
secondary pregnancy complication, 445 CTGs were performed. A DCM did not
occur. The minimum number of CTGs required to effect a DCM (NNT) was
therefore more than 445.
Table 2 summarises CTG-related costs in women with GDM. In the
subgroup of 95 women with GDM requiring combination therapy, the cost per
DCM was $2,660. In the subgroup of women with GDM managed by diet alone
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with a secondary pregnancy complication, the cost per DCM was $8,063. In the
subgroup of women with GDM managed by diet alone without a secondary
pregnancy complication, the cost per DCM could not be calculated as there
were no DCM. However, a total of $21,280 was spent on the 183 women in this
subgroup who underwent CTGs, ultrasounds and clinical reviews for no
apparent clinical return.

Discussion
There were several key findings in this study. Firstly, CTG is a useful
addition to the antenatal management of women with GDM who require
combination therapy (diet and medication) to achieve fasting and postprandial
glycaemic targets.20 For every 43 CTGs, a DCM occurred in this subgroup of
women. Our findings suggest that commencing CTG monitoring in GDM
pregnancies requiring combination therapy from 36 weeks gestation is
appropriate. .
In contrast, in the subgroup of women with GDM managed by diet
alone without a secondary pregnancy complication, CTG was not found to be
useful. After spending $21,280 for 183 women to have CTGs, ultrasounds and
clinical reviews, there was no apparent clinical return. Our results support the
arguments regarding the lack of utility of universal CTG monitoring in GDM
pregnancy managed by diet alone.17-19 Given one third of all CTGs in our study
were performed in women in this subgroup, there is clear scope to rationalize
hospital costs by refining clinical practice guidelines.
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The cost of management of GDM pregnancy is subject of debate. The
change in diagnostic criteria of GDM has resulted in rising prevalence in many
centres, especially where rates of maternal obesity are high.20,21 Concern has
been expressed that the cost and level of resources required to manage GDM
outweight the benefits.19,22,25 This has lead to some countries deciding against
adoption of the IADPSG 2010 criterion, in favour of higher glycaemic
thresholds.26 However, if the cost of managing GDM can be contained, and
clinical practice guidelines restrict CTG antenatal surveillance to women with
GDM pregnancy requiring combination therapy or with a secondary
complication, then it may be possible to adopt IADPSG diagnostic criteria
without straining obstetric services. This is important as women diagnosed with
GDM have an increased lifetime risk of type 2 diabetes and other
cardiovascular risk factors and the simple act of providing dietary counselling
and diabetic education may help with chronic disease prevention and result in
overall cost savings to the health system.27,28
The role of CTGs in women with GDM managed by diet alone with a
secondary pregnancy complication remains unclear. The NNT in our study was
161 at a cost of $8,063. A number of sources have advocated for CTG
monitoring if a secondary pregnancy complication is present in order to reduce
fetal and maternal risks.6,10 More work is required to define the types of
secondary complications that may benefit from CTG monitoring in order to
refine management in this subgroup.
One limitation of this study is that our hospital clinical practice guideline
offered delivery at 40 weeks. Therefore, the study is not able to comment on the
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utility of antenatal CTGs for fetal surveillance in women with GDM pregnancy
beyond 40 weeks. A second limitation is that the study sample was powered to
detect the NNT to effect a DCM. It was not powered to detect fetal death in
utero. We are therefore not able to comment on the efficacy of CTG to prevent
fetal demise.
In conclusion, there is a lack of research exploring the effectiveness of
antenatal surveillance using CTG in GDM pregnancy. Our findings suggest
CTGs are a useful addition to the antenatal management of women with GDM
requiring combination therapy (diet and medication). However, CTGs are not
useful in the subgroup of women managed by diet alone without a secondary
pregnancy complication. More research is required in the subgroup of women
with GDM managed by diet alone with a secondary pregnancy complication.
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Figure Legend
Figure 1: Number of CTGs to result in a “definitive change in management”
(DCM) within the three categories.

